rivaroxaban teva 2,5 mg filmdragerad tablett
teva gmbh - rivaroxaban - filmdragerad tablett - 2,5 mg - laktosmonohydrat hjälpämne; natriumlaurilsulfat hjälpämne; rivaroxaban 2 mg aktiv substans; rivaroxaban 0,5 mg aktiv substans
apixaban sandoz 5 mg filmdragerad tablett
sandoz a/s - apixaban - filmdragerad tablett - 5 mg - laktosmonohydrat hjälpämne; apixaban 5000 mg aktiv substans; natriumlaurilsulfat hjälpämne
rivaroxaban avansor 15 mg filmdragerad tablett
avansor pharma oy - rivaroxaban - filmdragerad tablett - 15 mg - laktosmonohydrat hjälpämne; rivaroxaban 15 mg aktiv substans; natriumlaurilsulfat hjälpämne
rivaroxaban avansor 20 mg filmdragerad tablett
avansor pharma oy - rivaroxaban - filmdragerad tablett - 20 mg - laktosmonohydrat hjälpämne; natriumlaurilsulfat hjälpämne; rivaroxaban 20 mg aktiv substans
rivaroxaban avansor 2,5 mg filmdragerad tablett
avansor pharma oy - rivaroxaban - filmdragerad tablett - 2,5 mg - laktosmonohydrat hjälpämne; rivaroxaban 2,5 mg aktiv substans; natriumlaurilsulfat hjälpämne
rivaroxaban viatris (previously rivaroxaban mylan)
mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotiska medel - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers. rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
apixaban viatris 5 mg filmdragerad tablett
viatris limited - apixaban - filmdragerad tablett - 5 mg - laktosmonohydrat hjälpämne; apixaban 5 mg aktiv substans; laktos (vattenfri) hjälpämne; natriumlaurilsulfat hjälpämne
rivaroxaban reddy 15 mg filmdragerad tablett
reddy holding gmbh - rivaroxaban - filmdragerad tablett - 15 mg - rivaroxaban 15 mg aktiv substans; natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne
rivaroxaban reddy 20 mg filmdragerad tablett
reddy holding gmbh - rivaroxaban - filmdragerad tablett - 20 mg - laktosmonohydrat hjälpämne; rivaroxaban 20 mg aktiv substans; natriumlaurilsulfat hjälpämne
rivaroxaban reddy 10 mg filmdragerad tablett
reddy holding gmbh - rivaroxaban - filmdragerad tablett - 10 mg - rivaroxaban 10 mg aktiv substans; laktosmonohydrat hjälpämne; natriumlaurilsulfat hjälpämne